Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 7 de 7
Filter
Add more filters










Database
Language
Publication year range
1.
PLoS One ; 10(11): e0143772, 2015.
Article in English | MEDLINE | ID: mdl-26600383

ABSTRACT

Newborn neurons are generated throughout life in two neurogenic regions, the subventricular zone and the hippocampal dentate gyrus. Stimulation of adult neurogenesis is considered as an attractive endogenous repair mechanism to treat different neurological disorders. Although tremendous progress has been made in our understanding of adult hippocampal neurogenesis, important questions remain unanswered, regarding the identity and the behavior of neural stem cells in the dentate gyrus. We previously showed that conditional Cre-Flex lentiviral vectors can be used to label neural stem cells in the subventricular zone and to track the migration of their progeny with non-invasive bioluminescence imaging. Here, we applied these Cre-Flex lentiviral vectors to study neurogenesis in the dentate gyrus with bioluminescence imaging and histological techniques. Stereotactic injection of the Cre-Flex vectors into the dentate gyrus of transgenic Nestin-Cre mice resulted in specific labeling of the nestin-positive neural stem cells. The labeled cell population could be detected with bioluminescence imaging until 9 months post injection, but no significant increase in the number of labeled cells over time was observed with this imaging technique. Nevertheless, the specific labeling of the nestin-positive neural stem cells, combined with histological analysis at different time points, allowed detailed analysis of their neurogenic potential. This long-term fate mapping revealed that a stable pool of labeled nestin-positive neural stem cells continuously contributes to the generation of newborn neurons in the mouse brain until 9 months post injection. In conclusion, the Cre-Flex technology is a valuable tool to address remaining questions regarding neural stem cell identity and behavior in the dentate gyrus.


Subject(s)
Genetic Vectors/genetics , Hippocampus/cytology , Lentivirus/genetics , Neurogenesis/physiology , Animals , Dentate Gyrus/cytology , Dentate Gyrus/metabolism , Hippocampus/metabolism , Mice , Nestin/metabolism , Neural Stem Cells/cytology , Neural Stem Cells/metabolism , Neurons/cytology , Neurons/metabolism
2.
Cell Stem Cell ; 16(5): 488-503, 2015 May 07.
Article in English | MEDLINE | ID: mdl-25957904

ABSTRACT

Adult hippocampal neurogenesis is believed to maintain a range of cognitive functions, many of which decline with age. We recently reported that radial neural stem cells (rNSCs) in the hippocampus undergo activation-dependent conversion into astrocytes, a mechanism that over time contributes to a reduction in the rNSC population. Here, we injected low and high levels of kainic acid (KA) in the dentate gyrus to assess whether neuronal hyperexcitation, a hallmark of epileptic disorders, could accelerate this conversion. At low levels of KA, generating epileptiform activity without seizures, we indeed found increased rNSC activation and conversion into astrocytes. At high levels, generating sustained epileptic seizures, however, we find that rNSCs divide symmetrically and that both mother and daughter cells convert into reactive astrocytes. Our results demonstrate that a threshold response for neuronal hyperexcitation provokes a dramatic shift in rNSC function, which impairs adult hippocampal neurogenesis in the long term.


Subject(s)
Astrocytes/physiology , Epilepsy/physiopathology , Hippocampus/cytology , Neural Stem Cells/physiology , Psychomotor Agitation/physiopathology , Adult , Animals , Cells, Cultured , Disease Models, Animal , Epilepsy/chemically induced , Humans , Kainic Acid/administration & dosage , Mice , Mice, Inbred C57BL , Neurogenesis
3.
Neurobiol Dis ; 69: 144-55, 2014 Sep.
Article in English | MEDLINE | ID: mdl-24878507

ABSTRACT

Brain injury following stroke affects neurogenesis in the adult mammalian brain. However, a complete understanding of the origin and fate of the endogenous neural stem cells (eNSCs) in vivo is missing. Tools and technology that allow non-invasive imaging and tracking of eNSCs in living animals will help to overcome this hurdle. In this study, we aimed to monitor eNSCs in a photothrombotic (PT) stroke model using in vivo bioluminescence imaging (BLI). In a first strategy, inducible transgenic mice expressing firefly luciferase (Fluc) in the eNSCs were generated. In animals that received stroke, an increased BLI signal originating from the infarct region was observed. However, due to histological limitations, the identity and exact origin of cells contributing to the increased BLI signal could not be revealed. To overcome this limitation, we developed an alternative strategy employing stereotactic injection of conditional lentiviral vectors (Cre-Flex LVs) encoding Fluc and eGFP in the subventricular zone (SVZ) of Nestin-Cre transgenic mice, thereby specifically labeling the eNSCs. Upon induction of stroke, increased eNSC proliferation resulted in a significant increase in BLI signal between 2days and 2weeks after stroke, decreasing after 3months. Additionally, the BLI signal relocalized from the SVZ towards the infarct region during the 2weeks following stroke. Histological analysis at 90days post stroke showed that in the peri-infarct area, 36% of labeled eNSC progeny differentiated into astrocytes, while 21% differentiated into mature neurons. In conclusion, we developed and validated a novel imaging technique that unequivocally demonstrates that nestin(+) eNSCs originating from the SVZ respond to stroke injury by increased proliferation, migration towards the infarct region and differentiation into both astrocytes and neurons. In addition, this new approach allows non-invasive and specific monitoring of eNSCs over time, opening perspectives for preclinical evaluation of candidate stroke therapeutics.


Subject(s)
Brain/physiopathology , Luminescent Measurements/methods , Neural Stem Cells/physiology , Neurogenesis , Optical Imaging/methods , Stroke/physiopathology , Animals , Astrocytes/pathology , Astrocytes/physiology , Brain/pathology , Cell Movement/physiology , Disease Progression , Follow-Up Studies , Mice, Transgenic , Neural Stem Cells/pathology , Neurons/pathology , Neurons/physiology , Stroke/pathology , Time Factors
4.
Curr Pharm Des ; 20(23): 3763-75, 2014.
Article in English | MEDLINE | ID: mdl-24180394

ABSTRACT

Thirteen years have passed since the neurogenic hypothesis of depression was postulated. One of its aspects, that decreased neurogenesis could be causative of the onset of depression has been difficult to prove. Another aspect, the prediction that increasing neurogenesis would not only be supportive but also required to produce clinical results by antidepressants has gathered experimental validation. Thus a question arises: should new antidepressant strategies based solely on increasing neurogenesis be pursued? At the risk of disappointing the audience, we will not provide a straight answer to this question in this review, but we do hope to enlighten the reader regarding what is known about adult hippocampal neurogenesis, the indications and evidence of its involvement in the onset and treatment of depression, and the advances that have been made in the field in recent years. As we will recount here, the main body of support in favor of the neurogenic hypothesis of depression is based more on intimation than actual proof. However the rare examples that provide support are sufficiently robust to justify investment of resources and effort to clarify the issue, even if the involvement of neurogenesis, both in the etiology and the treatment of depression, is only partial and comprises only subtle components of this complex mental disorder.


Subject(s)
Antidepressive Agents/pharmacology , Depression/drug therapy , Drug Discovery/methods , Hippocampus/drug effects , Neurogenesis/drug effects , Animals , Antidepressive Agents/administration & dosage , Antidepressive Agents/therapeutic use , Biogenic Amines/metabolism , Depression/metabolism , Depression/pathology , Depression/physiopathology , Disease Models, Animal , Electroconvulsive Therapy , Hippocampus/pathology , Hippocampus/physiopathology , Humans , Neural Stem Cells/drug effects , Neural Stem Cells/metabolism , Neural Stem Cells/pathology
5.
Curr Pharm Des ; 20(23): 3751-62, 2014.
Article in English | MEDLINE | ID: mdl-24180399

ABSTRACT

The regulation of the activity of brain monoaminergic systems has been the focus of attention of many studies since the first antidepressant drug emerged 50 years ago. The search for novel antidepressants is deeply linked to the search for fast-acting strategies, taking into account that 2-4 weeks of treatment with classical antidepressant are required before clinical remission of the symptoms becomes evident. In the recent years several hypotheses have been proposed on the basis of the existence of alterations in brain synaptic plasticity in major depression. Recent evidences support a role for 5-HT4 receptors in the pathogenesis of depression as well as in the mechanism of action of antidepressant drugs. In fact, chronic treatment with antidepressant drugs appears to modulate, at different levels, the signaling pathway associated to 5-HT4 receptors, as well as their levels of expression in the brain. Moreover, several experimental studies have identified this receptor subtype as a promising new target for fast-acting antidepressant strategy: the administration of partial agonists of this receptor induces a number of responses similar to those observed after chronic treatment with classical antidepressants, but with a rapid onset of action. They include efficacy in behavioral models of depression, rapid desensitization of 5-HT1A autoreceptors, and modifications in the expression of several molecular markers of brain neuroplasticity. Although much work remains to be done in order to clarify the real therapeutic potential of these drugs, the evidences reviewed below support the hypothesis that 5-HT4 receptor partial agonists could behave as rapid and effective antidepressants.


Subject(s)
Antidepressive Agents/therapeutic use , Depression/drug therapy , Drug Discovery/methods , Receptors, Serotonin, 5-HT4/metabolism , Serotonin 5-HT4 Receptor Agonists/therapeutic use , Animals , Antidepressive Agents/administration & dosage , Brain/drug effects , Brain/metabolism , Cognition/drug effects , Depression/metabolism , Depression/psychology , Disease Models, Animal , Humans , Neuronal Plasticity/drug effects , Protein Binding , Serotonin 5-HT4 Receptor Agonists/administration & dosage , Synaptic Transmission/drug effects , Time Factors
6.
Neural Plast ; 2013: 537265, 2013.
Article in English | MEDLINE | ID: mdl-23862076

ABSTRACT

It is widely accepted that changes underlying depression and antidepressant-like effects involve not only alterations in the levels of neurotransmitters as monoamines and their receptors in the brain, but also structural and functional changes far beyond. During the last two decades, emerging theories are providing new explanations about the neurobiology of depression and the mechanism of action of antidepressant strategies based on cellular changes at the CNS level. The neurotrophic/plasticity hypothesis of depression, proposed more than a decade ago, is now supported by multiple basic and clinical studies focused on the role of intracellular-signalling cascades that govern neural proliferation and plasticity. Herein, we review the state-of-the-art of the changes in these signalling pathways which appear to underlie both depressive disorders and antidepressant actions. We will especially focus on the hippocampal cellularity and plasticity modulation by serotonin, trophic factors as brain-derived neurotrophic factor (BDNF), and vascular endothelial growth factor (VEGF) through intracellular signalling pathways-cAMP, Wnt/ ß -catenin, and mTOR. Connecting the classic monoaminergic hypothesis with proliferation/neuroplasticity-related evidence is an appealing and comprehensive attempt for improving our knowledge about the neurobiological events leading to depression and associated to antidepressant therapies.


Subject(s)
Antidepressive Agents/therapeutic use , Cell Proliferation/drug effects , Depressive Disorder/drug therapy , Hippocampus/drug effects , Neuronal Plasticity/drug effects , Antidepressive Agents/pharmacology , Depressive Disorder/physiopathology , Hippocampus/physiopathology , Humans , Neuronal Plasticity/physiology , Signal Transduction/drug effects , Signal Transduction/physiology
7.
Int J Neuropsychopharmacol ; 15(5): 631-43, 2012 Jun.
Article in English | MEDLINE | ID: mdl-21733238

ABSTRACT

It has been recently suggested that activation of 5-HT4 receptors might exert antidepressant-like effects in rats after 3 d treatment, suggesting a new strategy for developing faster-acting antidepressants. We studied the effects of 3 d and 7 d treatment with the 5-HT4 receptor partial agonist RS67333 (1.5 mg/kg.d) in behavioural tests of chronic efficacy and on neuroplastic-associated changes, such as adult hippocampal neurogenesis, expression of CREB, BDNF, ß-catenin, AKT and 5-HT4 receptor functionality. RS67333 treatment up-regulated hippocampal cell proliferation, ß-catenin expression and pCREB/CREB ratio after 3 d treatment. This short-term treatment also reduced immobility time in the forced swim test (FST), together with a partial reversion of the anhedonic-like state (sucrose consumption after chronic corticosterone). Administration of RS67333 for 7 d resulted in a higher increase in the rate of hippocampal cell proliferation, a significant desensitization of 5-HT4 receptor-coupled adenylate cyclase activity and a more marked increase in the expression of neuroplasticity-related proteins (BDNF, CREB, AKT): these changes reached the same magnitude as those observed after 3 wk administration of classical antidepressants. Consistently, a positive behavioural response in the novelty suppressed feeding (NSF) test and a complete reversion of the anhedonic-like state (sucrose consumption) were also observed after 7 d treatment. These results support the antidepressant-like profile of RS67333 with a shorter onset of action and suggest that this time period of administration (3-7 d) could be a good approximation to experimentally predict the onset of action of this promising strategy.


Subject(s)
Aniline Compounds/pharmacology , Behavior, Animal/drug effects , Gene Expression Regulation/drug effects , Hippocampus/drug effects , Nerve Tissue Proteins/drug effects , Neural Pathways/drug effects , Neurogenesis/drug effects , Neuronal Plasticity/drug effects , Piperidines/pharmacology , Aniline Compounds/administration & dosage , Animals , Antidepressive Agents/pharmacology , Male , Piperidines/administration & dosage , Rats , Rats, Sprague-Dawley
SELECTION OF CITATIONS
SEARCH DETAIL
...